HomeCompareOMGA vs PFE

OMGA vs PFE: Dividend Comparison 2026

OMGA yields 1402.52% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OMGA wins by $381345977.97M in total portfolio value
10 years
OMGA
OMGA
● Live price
1402.52%
Share price
$0.14
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$381345978.01M
Annual income
$334,438,358,870,850.44
Full OMGA calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — OMGA vs PFE

📍 OMGA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOMGAPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OMGA + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OMGA pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OMGA
Annual income on $10K today (after 15% tax)
$119,214.59/yr
After 10yr DRIP, annual income (after tax)
$284,272,605,040,222.90/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, OMGA beats the other by $284,272,605,017,903.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OMGA + PFE for your $10,000?

OMGA: 50%PFE: 50%
100% PFE50/50100% OMGA
Portfolio after 10yr
$190672989.03M
Annual income
$167,219,179,448,554.60/yr
Blended yield
87.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

OMGA
No analyst data
Altman Z
-5.0
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OMGA buys
0
PFE buys
0
No recent congressional trades found for OMGA or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOMGAPFE
Forward yield1402.52%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$381345978.01M$49.6K
Annual income after 10y$334,438,358,870,850.44$26,258.71
Total dividends collected$377907407.35M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OMGA vs PFE ($10,000, DRIP)

YearOMGA PortfolioOMGA Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$150,952$140,252.45$9,153$693.39+$141.8KOMGA
2$2,140,160$1,978,640.40$8,593$849.25+$2.13MOMGA
3$28,507,337$26,217,366.21$8,336$1,066.78+$28.50MOMGA
4$356,877,024$326,374,173.75$8,437$1,384.80+$356.87MOMGA
5$4,200,368,557$3,818,510,141.40$9,013$1,875.40+$4200.36MOMGA
6$46,497,265,746$42,002,871,390.15$10,306$2,680.72+$46497.26MOMGA
7$484,297,536,606$434,545,462,256.76$12,820$4,101.38+$484297.52MOMGA
8$4,748,158,615,450$4,229,960,251,282.26$17,673$6,826.70+$4748158.60MOMGA
9$43,838,896,396,104$38,758,366,677,572.48$27,543$12,591.86+$43838896.37MOMGA
10$381,345,978,014,682$334,438,358,870,850.44$49,560$26,258.71+$381345977.97MOMGA

OMGA vs PFE: Complete Analysis 2026

OMGAStock

Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Full OMGA Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this OMGA vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OMGA vs SCHDOMGA vs JEPIOMGA vs OOMGA vs KOOMGA vs MAINOMGA vs JNJOMGA vs MRKOMGA vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.